SINOPHARM GROUP 1/5/O.N. risk profile
51 Elevated one input has moved against it
Measured 21 October 2026 from X2S1's filed statements. Recomputed nightly.
51 (Elevated), driven by Competitive position at 68, over 5 weighted categories on the MANUFACTURER profile.
What is measured
| Mechanism | Reading | Band | Direction | Driver |
|---|---|---|---|---|
| Market expectation | 57 | Elevated | Stable | Drawdown from the 52-week high — 25.0% |
| Operating pressure | 42 | Elevated | Worsening | Costs outgrowing revenue — +0.1 percentage points |
| Cash conversion | 29 | Normal | Easing | Free-cash-flow margin — 2.2% |
| Leverage and coverage | 27 | Normal | Stable | Current ratio — 1.41x |
| Competitive position | 68 | Stretched | Stable | Operating-margin gap against peers — -4.6 percentage points |
| Concentration | Reads identified supplier spend, customers above the 10% disclosure threshold and revenue by region. No reading is stored for this company. | |||
These are descriptive readings of disclosed mechanisms, not investment advice, and not a prediction. A band says where a measured input sits, never what to do about it or what happens next.
Healthcare companies with a risk reading
Lilly(Eli) & Company 33Johnson & Johnson 39Abbvie Inc 57Unitedhealth Group Inc 43Roche Holding AG 35Merck & Co Inc 35Novartis AG 29Novartis AG 31Astrazeneca plc 33Thermo Fisher Scientific Inc 44AMGEN Inc 47Gilead Sciences Inc 51
Financials, valuation and price history for SINOPHARM GROUP 1/5/O.N.